NEW YORK (GenomeWeb) – GlaxoSmithKline and 23andMe announced today that they have signed a four-year drug discovery collaboration deal in which both partners will initially contribute 50 percent of the funding, will have the ability to advance targets together or independently, and will share in the proceeds from any new drugs developed within the partnership.

Additionally, GSK said it has made a $300 million equity investment in 23andMe.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.